Accelerating the translation of therapeutic innovation into clinical impact

Democratizing access to rapid, high-quality biomanufacturing with portable CMC

About Us

A new path for drug developers

Accelerating clinical impact requires innovative outsourcing. Through parallel integration of our development platform with preclinical drug discovery, our comprehensive discovery-to-IND program offers a completely new path for drug developers that is faster, easier, and more predictable.

Built for speed

Our discovery-to-IND program cuts clinical scale-up timelines in half, saving 6-9 months on your way to the clinic. Built for speed, our fixed fees, guaranteed timelines, and minimum yield of GMP drug substance ensure that your critical Phase 1 milestones are predictably achieved.

Win together

Our unique, integrated offering connects discovery with development, our scientists to your development team, and our success to your success, creating a singular focus and lasting collaborative relationship. We share risks and win together.

Our Leadership Team

Jesse McCool PhD

 

CEO and Co-Founder

Yuk Chun Chiu

 

Chief Manufacturing Officer

Stephen Hamilton PhD

 

Chief Technical Officer

Christa Short

 

VP Process Development

David Schmidt

 

VP Analytical Development

Mike Brem

 

Director of Cell Line Development

To Be Announced Soon

VP Quality Assurance and Regulatory Affairs

Our Board

Christian Kanady

 

Errik Anderson

 

Jesse McCool PhD

 

Our Advisory Board

Howard Levine PhD

 

Roger Lias PhD

 

Manon Cox PhD

 

John Mott PhD

 

Anshul Mangal

 

Edwin Beale

 

Mike O’Mara

 

Peter Rock

 

Gabriel McCool PhD

 

Lynne Frick

 

Marc Helouin

 

Piotr Bobrowicz PhD

 

Join our team

Built by scientists for scientists

We are a growing team of drug development professionals who share a passion for speed to clinical impact through collaboration.

Join our community

Connect with our BD team